Return to homepagePandemic Pact

Anti-Coronavirus Therapy (ACT) to prevent COVID-19 disease progression: a clinical trial platform

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 172627

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2020

  • Known Financial Commitments (USD)

    $2,202,839.25

  • Funder

    Canadian Institutes of Health Research (CIHR)

  • Principal Investigator

    Sonia Savitri Anand, Alvaro Avezum, Shrikant I Bangdiwala, Emilie Prudence Belley-Côté, Noel Chan, Shurjeel Choudhri, Antonio Limcaco Dans, Rafael Diaz, John Wa Eikelboom, Michael Eand Camilo Farkouh, Hertzel C Felix, Jeff Sean Gerstein, Sanjit Singh Healey, Darryl Jolly, Mark Bertram Leong, Jose Patricio Loeb, Guillaume Lopéz, Richard Paré, Salim Whitlock

  • Research Location

    Canada

  • Lead Research Institution

    McMaster University Medicine

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Controlled Clinical Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

COVID-19 has been diagnosed in millions of persons and has caused several hundred thousand deaths. Effective treatments are urgently required. We have created the "Anti-Coronavirus Therapies (ACT) to prevent COVID-19 disease progression" trials platform to rapidly evaluate whether several commonly available interventions can be repurposed for the treatment of COVID-19 disease. The specific aims of our research are to determine whether treatments that: (a) reduce the levels of virus in the body, (b) reduce the response by the body to the infection (i.e., inflammation), and (c) prevent blood clotting can prevent COVID-19 disease progression. We will test these treatments alone and in combination in two trials: (1) Outpatient trial: here we are trying to patients diagnosed with COVID-19 from needing to go to hospital. (2) Inpatient trial: here we are trying to prevent patients with COVID-19 who are already hospitalized from being admitted to the intensive care unit and from dying. The trial started in Canada on April 21 and will eventually include about 4,000 patients from at least 100 centres and at least 12 countries around the world.